Which Tests Do You Need and When?
Cancer screening aims to detect certain cancers — or changes that may develop into cancer — before symptoms appear.
But there is no single screening programme that is right for everyone, and there is currently no routine test that can reliably screen the whole body for every type of cancer.
The appropriate screening depends on several factors:
Age
Sex
Personal medical history
Family history of cancer
Smoking history
Previous screening results
Inherited cancer risk
Other disease-specific risk factors
Some cancer screening programmes have strong evidence supporting their use in the general population. Others are recommended only for people with particular risk factors.
The objective is not to perform as many cancer tests as possible. It is to identify which screening is appropriate for the individual, when it should begin, and what should happen if an abnormality is found.
What Cancer Screening Tests Do I Need?
For people without symptoms and at average risk, the most established screening pathways focus primarily on breast, cervical and colorectal cancer. WHO specifically identifies these as cancers for which organised population screening can be supported by evidence.
Other screening may be appropriate for selected individuals.
Lung cancer screening is recommended for people meeting defined smoking-related risk criteria.
Prostate cancer screening may involve PSA testing following an informed discussion about potential benefits and limitations.
People with significant family histories, inherited cancer syndromes or certain medical conditions may require entirely different surveillance programmes.
This is why age is useful as a starting point — but age alone should not determine cancer screening.
Cancer Screening by Age
Cancer Screening Under 40
For most average-risk adults under 40, extensive cancer imaging or broad cancer blood testing is not routinely recommended.
Important considerations during this period include cervical cancer screening, assessment of significant family history, and recognition of inherited cancer risk.
WHO recommends HPV DNA-based cervical screening beginning at age 30 for the general population of women, with earlier screening beginning at 25 for women living with HIV. National screening programmes may use different starting ages and intervals.
People with strong family histories or recognised hereditary cancer syndromes may require screening substantially earlier than the general population.
And age-based screening recommendations apply only to people without concerning symptoms. A suspicious symptom should be investigated regardless of age.
Cancer Screening Between 40 and 49
This is when several major screening discussions begin.
Breast Cancer Screening
Mammography is the principal breast cancer screening test.
Guidelines differ somewhat between organisations and countries. For example, the American Cancer Society allows average-risk women aged 40–44 to choose annual mammography and recommends annual screening from 45–54. From age 55, women may transition to every two years or continue annually. Other programmes use biennial mammography beginning at 40.
Women at increased inherited or familial risk may require an earlier or more intensive programme, sometimes including breast MRI in addition to mammography.
Breast ultrasound may provide useful additional information in selected situations, but it is not a universal replacement for mammography.
Colorectal Cancer Screening
For adults at average risk, current American Cancer Society guidance recommends beginning colorectal cancer screening at age 45.
Available approaches include:
Colonoscopy
FIT — faecal immunochemical testing
High-sensitivity stool-based testing
and selected newer screening options.
The appropriate test and interval depend on the screening method and individual risk.
Cancer Screening Between 50 and 69
For many people, this is the period during which several established cancer screening programmes overlap.
Depending on sex and individual risk, screening considerations may include:
Mammography for breast cancer
Cervical screening with HPV-based testing
Colorectal cancer screening
Low-dose CT for eligible people at increased lung cancer risk
Discussion of PSA testing for prostate cancer
But these tests should not automatically be bundled into the same package for everyone.
Personal and family history can substantially change what is appropriate.
Cancer Screening After 70
Cancer screening does not automatically stop at one particular birthday.
Whether screening should continue increasingly depends on overall health, previous screening history, individual cancer risk, life expectancy and whether detecting a cancer would lead to meaningful further treatment.
For example, current ACS colorectal guidance recommends routine screening through age 75 for average-risk adults in good health with a life expectancy greater than 10 years. Between 76 and 85, screening becomes an individual decision; screening is not recommended after 85.
Different cancers have different upper-age recommendations.
Cancer Screening for Women
Cancer screening for women may include several different pathways depending on age and risk.
Breast Cancer Screening
For average-risk women, mammography remains the primary screening method.
Women at higher risk because of genetic mutations, significant family history, previous chest radiation or other recognised factors may require a different programme.
This can include earlier mammography and, for selected high-risk women, breast MRI.
Cervical Cancer Screening: HPV Testing and Pap Smear
Cervical cancer screening is particularly important because it can identify precancerous changes before invasive cervical cancer develops.
WHO recommends HPV DNA testing as the preferred primary screening approach where available.
Screening programmes may use:
Primary high-risk HPV testing
HPV testing followed by cytology or other triage
Cervical cytology — Pap smear — where appropriate
WHO also issued updated guidance in May 2026 addressing HPV DNA genotyping and its use for risk stratification within cervical screening programmes.
An abnormal HPV or cytology result does not mean that cervical cancer is present. Depending on the finding, further assessment such as colposcopy and biopsy may be required.
Cancer Screening for Men
There is no single “male cancer screening package” appropriate for every man.
The main considerations include colorectal screening, lung screening for eligible smokers or former smokers, and individualised discussion of prostate cancer screening.
Prostate Cancer Screening: When Should PSA Be Checked?
The PSA blood test can help identify men who may require further prostate assessment.
But PSA is not cancer-specific. An elevated result does not automatically mean prostate cancer.
WHO does not recommend systematic population-wide PSA screening simply because all men have reached a particular age.
The American Cancer Society instead recommends informed discussion about PSA screening beginning around:
Age 50 for men at average risk with sufficient life expectancy
Age 45 for men at higher risk
Age 40 for selected men at particularly high familial risk.
If PSA is abnormal, further evaluation may include repeat PSA testing, clinical assessment, prostate MRI, additional risk assessment and, when indicated, biopsy.
Lung Cancer Screening: Who Should Have a Low-Dose CT?
Lung cancer screening is not intended for everyone.
The established screening examination is low-dose CT — LDCT, not a standard chest X-ray and not a routine high-resolution CT performed indiscriminately.
Eligibility is based primarily on age and smoking exposure.
Major current guidelines recommend LDCT screening for selected adults at increased risk because of substantial smoking history. Exact criteria differ somewhat between organisations, which is why smoking exposure should be assessed before screening is arranged.
The key principle is simple:
A CT scan should not be added to a cancer check-up simply because more imaging sounds more comprehensive.
Colorectal Cancer Screening: Colonoscopy, Stool Tests and New Blood Tests
Colorectal cancer screening is particularly important because some methods can identify precancerous polyps as well as cancer.
Current screening options include colonoscopy and validated stool-based tests.
People with previous colorectal polyps, inflammatory bowel disease, significant family history or inherited colorectal cancer syndromes may require earlier or more frequent colonoscopy than average-risk adults.
Can a Blood Test Screen for Colorectal Cancer?
This area has recently changed.
In 2024, the FDA approved Shield, a blood-based colorectal cancer screening test for average-risk adults aged 45 and older. A positive result requires colonoscopy. The test is not intended to replace diagnostic or surveillance colonoscopy in higher-risk patients.
In May 2026, the American Cancer Society updated its colorectal screening guideline to include blood-based screening among the available options.
However, colonoscopy and high-sensitivity stool-based methods remain preferred options, partly because current blood-based tests are less effective at detecting precancerous lesions and early-stage cancers.
So the arrival of a cancer blood test does not mean colonoscopy has become obsolete.
Cancer Screening With a Family History of Cancer
Family history can change screening considerably.
Earlier or specialised assessment may be appropriate when a family contains:
Multiple relatives with the same or related cancers
Cancer diagnosed at unusually young ages
Breast and ovarian cancer patterns
Colorectal and endometrial cancer patterns
Multiple prostate or pancreatic cancers
A known inherited cancer-associated genetic variant
In these situations, simply ordering more scans may not be the best first step.
Genetic counselling and appropriately selected germline testing may help determine whether an inherited cancer predisposition is present and which surveillance programme is appropriate.
Are There Screening Tests for Ovarian, Pancreatic and Liver Cancer?
Not every cancer has an established population screening test.
For average-risk people without symptoms, routine population screening is not currently established for many cancers, including pancreatic and ovarian cancer.
That does not mean these cancers can never be monitored.
Certain high-risk groups may require specific surveillance.
For example, people with particular inherited cancer syndromes may qualify for specialised pancreatic surveillance. Patients with certain chronic liver diseases or cirrhosis may require surveillance for hepatocellular carcinoma.
These are risk-based surveillance programmes, not general cancer screening for everyone.
Can Tumour Markers Detect Cancer Early?
Patients frequently ask whether a blood panel containing tumour markers can be used as a general cancer check.
Usually, this is not an appropriate screening strategy.
Tests such as:
CEA
CA 19-9
CA-125
CA 15-3
AFP
can be clinically useful in particular diseases and circumstances.
But they are not universal cancer screening tests.
Non-cancerous conditions can increase some tumour markers, while some cancers may be present without causing an abnormal marker.
Ordering multiple tumour markers in healthy people can therefore result in both false reassurance and unnecessary investigations.
Can PET/CT Be Used for Cancer Screening?
PET/CT is not a routine general cancer-screening examination for healthy people without symptoms.
It can be extremely valuable when there is an appropriate oncological indication, but that is different from using it to search indiscriminately for cancer.
Whole-body CT presents similar concerns, including unnecessary radiation exposure and incidental findings that can lead to further testing.
Whole-body MRI avoids ionising radiation and has defined uses in some high-risk conditions, but it should not automatically be considered a universal cancer-screening test either.
More imaging is not necessarily better screening.
Can One Blood Test Detect Multiple Cancers?
This is one of the most closely watched areas of early cancer detection.
Multi-cancer detection (MCD or MCED) blood tests attempt to identify biological signals associated with several cancers from a single blood sample.
Research includes signals involving:
Circulating DNA
DNA methylation
DNA fragmentation
RNA
Proteins
and combinations of different biomarkers.
The technology is promising, but the distinction between detecting a biological signal and demonstrating that population screening improves meaningful health outcomes is crucial.
As of 2026, the U.S. National Cancer Institute states that no MCD test has FDA approval for cancer screening and that their effectiveness in asymptomatic populations still requires evaluation in randomized clinical trials.
These tests therefore should not replace established breast, cervical, colorectal or eligible lung cancer screening.
Screening Is Different From Investigating Symptoms
This distinction is extremely important.
Screening is for people without symptoms.
Someone with a new breast lump, unexplained bleeding, persistent blood in the stool, unexplained weight loss, persistent cough, abnormal lymph nodes or another concerning symptom may require diagnostic investigation rather than routine screening.
That pathway could involve specialist examination, targeted imaging, endoscopy, laboratory testing or biopsy depending on the clinical problem.
Likewise, an abnormal screening result does not mean that a person has cancer.
It means that the finding needs to be interpreted and, when appropriate, investigated further.
Cancer Screening Should Be Personalised – Not Maximised
A comprehensive cancer assessment does not mean ordering every available scan and blood test.
A more appropriate starting point is:
Age + Sex + Family History + Personal History + Smoking Exposure + Previous Screening + Genetic Risk + Relevant Medical Conditions
From there, the appropriate screening pathway can be selected.
One person may need routine age-appropriate screening.
Another may qualify for annual low-dose CT because of smoking history.
Someone with significant inherited breast cancer risk may need breast MRI in addition to mammography.
A person with previous colorectal polyps may require a specific colonoscopy surveillance interval.
And another healthy person may need no additional cancer testing beyond established screening recommendations.
Cancer Screening and Early Detection in Türkiye
Some international patients travel to Türkiye for routine screening, while others seek further investigation because a previous test performed at home has identified an abnormality.
These are different situations and should be approached differently.
If screening is appropriate, the programme should be based on the person’s age and individual cancer risk rather than a predetermined collection of scans and tumour markers.
If an abnormality has already been identified, repeating a general check-up may add little value. The priority may instead be specialist review, comparison of previous imaging, targeted diagnostic testing or biopsy.
And if cancer is confirmed, the pathway changes again — from screening and diagnosis to staging, multidisciplinary assessment and treatment planning.
Cancer Screening Abroad: How Healing Journey Coordinates the Process
Healing Journey coordinates cancer screening and further diagnostic assessment in Türkiye according to the patient’s medical needs rather than offering the same cancer-screening package to everyone.
Before planning investigations, available medical history, previous screening, family history, risk factors and existing results can be reviewed to determine what is actually relevant and what may not need to be repeated.
When additional investigation is required, our medical team can coordinate the appropriate specialists, imaging, endoscopy, laboratory assessment or biopsy as clinically indicated.
If an abnormal finding leads to a cancer diagnosis, the same pathway can continue through appropriate specialist review, staging and treatment planning.
For international patients, results, imaging and medical documentation can also be organised so that care can continue with their physicians after returning home.
The objective is not simply to complete a collection of tests in Türkiye.
It is to create a medically appropriate screening or diagnostic pathway and ensure that any important finding has a clear next step.
References
World Health Organization (WHO). Cancer Screening and Early Detection.
World Health Organization. Guidelines for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention.
World Health Organization. HPV DNA Genotyping Guideline, May 2026.
American Cancer Society (ACS). Cancer Screening Guidelines.
American Cancer Society. Colorectal Cancer Screening Guideline, May 2026.
American Cancer Society. Breast Cancer Screening Recommendations.
American Cancer Society. Prostate Cancer Early Detection Recommendations.
National Cancer Institute (NCI). Cancer Screening and Multi-Cancer Detection Tests.
U.S. Food and Drug Administration (FDA). Shield Blood-Based Colorectal Cancer Screening Test.
